{"id":3568,"date":"2021-11-17T19:22:41","date_gmt":"2021-11-17T17:22:41","guid":{"rendered":"https:\/\/covid-19-bilgi.de\/?page_id=3568"},"modified":"2022-12-15T11:05:41","modified_gmt":"2022-12-15T09:05:41","slug":"guclendirici-asi","status":"publish","type":"page","link":"https:\/\/covid-19-bilgi.de\/tr\/guclendirici-asi\/","title":{"rendered":"G\u00fc\u00e7lendirici A\u015f\u0131"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

COVID-19'a Kar\u015f\u0131 Tazeleme A\u015f\u0131lar\u0131<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

G\u00fc\u00e7lendirici A\u015f\u0131lar<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Mevcut Omikron dalgas\u0131nda, tazeleme a\u015f\u0131lar\u0131 olarak da bilinen g\u00fc\u00e7lendirici a\u015f\u0131lar \u00f6zellikle \u00f6nemlidir. Daim\u00ee A\u015f\u0131 Komisyonu (STIKO), risk gruplar\u0131 i\u00e7in ikinci bir tazeleme a\u015f\u0131s\u0131 \u00f6nermektedir. Kimlere tazeleme a\u015f\u0131n\u0131n gerekti\u011fini ve kapsaml\u0131 koruma i\u00e7in g\u00fc\u00e7lendirici a\u015f\u0131n\u0131n neden \u00e7ok \u00f6nemli oldu\u011funu ve g\u00fc\u00e7lendirici a\u015f\u0131 ile ilgili t\u00fcm bilgileri burada bulabilirsiniz.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131 neden gereklidir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Almanya’da yayg\u0131n olan olduk\u00e7a bula\u015f\u0131c\u0131 omikron varyant\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, kendi korunman\u0131z ve sa\u011fl\u0131k sisteminin a\u015f\u0131r\u0131 y\u00fcklenmesini \u00f6nlemek i\u00e7in tazeleme a\u015f\u0131s\u0131 \u00f6zellikle \u00f6nemlidir. \u00c7\u00fcnk\u00fc uzun zaman \u00f6nce a\u015f\u0131lar\u0131 tamamlanm\u0131\u015f veya ilerlemi\u015f ya\u015ftan ya da \u00f6nceki hastal\u0131klar nedeniyle ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi zay\u0131flam\u0131\u015f ki\u015filerde zamanla ba\u011f\u0131\u015f\u0131kl\u0131k korumas\u0131 da azal\u0131r. Ancak bu do\u011fal bir s\u00fcre\u00e7tir: Prensip olarak ba\u011f\u0131\u015f\u0131kl\u0131k sistemi, korona vir\u00fcsle nas\u0131l h\u0131zl\u0131 ve etkili bir \u015fekilde m\u00fccadele edece\u011fini yava\u015f yava\u015f unutur.<\/p>

Bu nedenle v\u00fccudun a\u015f\u0131 korumas\u0131n\u0131 tazeleme a\u015f\u0131s\u0131 ile g\u00fc\u00e7lendirerek iyile\u015ftirmek \u00f6nemlidir – STIKO \u015fimdi \u00f6zellikle risk alt\u0131nda olan ki\u015filere kapsaml\u0131 koruma i\u00e7in ikinci bir tazeleme a\u015f\u0131s\u0131 bile \u00f6nermektedir. \u00c7\u00fcnk\u00fc \u015fu durum hala ge\u00e7erli: Korona a\u015f\u0131s\u0131, hastal\u0131\u011f\u0131n ciddi ve \u00f6l\u00fcmc\u00fcl seyrine kar\u015f\u0131 en etkili korumad\u0131r. COVID-19 hastalar\u0131n\u0131n hastaneye yat\u0131\u015f say\u0131s\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde azalt\u0131r. Bu, RKI raporlar\u0131ndaki a\u015f\u0131lama etkinli\u011fine ili\u015fkin s\u00fcrekli g\u00fcncellenen verilerle g\u00f6sterilmektedir. ABD’den gelen veriler g\u00f6steriyor ki: \u00dc\u00e7 korona a\u015f\u0131s\u0131 ile ciddi hastal\u0131klara kar\u015f\u0131 koruma neredeyse y\u00fczde 100’e \u00e7\u0131k\u0131yor.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131lar hangileridir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

BioNTech\/Pfizer ve Moderna\u2019dan \u00f6zel ayarlanm\u0131\u015f Omikron a\u015f\u0131lar\u0131na ye\u015fil \u0131\u015f\u0131k<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

COVID-19 pandemisinin geli\u015fimi ve koronavir\u00fcs SARS-CoV-2’nin yeni vir\u00fcs varyantlar\u0131n\u0131n \u00fcremesi dinamik s\u00fcre\u00e7lerdir. Bu nedenle korona a\u015f\u0131lar\u0131, \u00f6rne\u011fin korona vir\u00fcs\u00fcn\u00fcn \u015fu anda bask\u0131n olan Omikron alt varyantlar\u0131na kar\u015f\u0131 y\u00fcksek d\u00fczeyde bir ba\u011f\u0131\u015f\u0131kl\u0131k korumas\u0131n\u0131 garanti edebilmek i\u00e7in s\u00fcrekli olarak geli\u015ftirilmektedir.<\/p>

Eyl\u00fcl 2022’de Avrupa Komisyonu, BioNTech\/Pfizer ve Moderna’n\u0131n omikron varyant\u0131na uyarlanm\u0131\u015f Corona a\u015f\u0131lar\u0131n\u0131 onaylad\u0131.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131 nas\u0131l etki eder?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici (Booster) a\u015f\u0131, tazeleme a\u015f\u0131s\u0131n\u0131n e\u015f anlam\u0131d\u0131r. “Booster” terimi \u0130ngilizce’den gelir ve anlam\u0131 “g\u00fc\u00e7lendirici” dir. Tazeleme a\u015f\u0131lamas\u0131yla, azalan ba\u011f\u0131\u015f\u0131kl\u0131k korumas\u0131 basit ve etkili bir \u015fekilde g\u00fc\u00e7lendirilebilir. \u00c7\u00fcnk\u00fc g\u00fc\u00e7lendirici ile ba\u011f\u0131\u015f\u0131kl\u0131k sisteminiz korona vir\u00fcs\u00fc tekrar hat\u0131rlar ve b\u00f6ylece onunla m\u00fccadeleye daha iyi haz\u0131rlan\u0131r. Bu \u015fekilde tazeleme a\u015f\u0131s\u0131, a\u015f\u0131 korumas\u0131n\u0131n \u2013 ilerleyen ya\u015f veya \u00f6nceki hastal\u0131klardan ba\u011f\u0131ms\u0131z olarak – etkili bir \u015fekilde s\u00fcrd\u00fcr\u00fclmesini sa\u011flar ve vir\u00fcs\u00fcn daha fazla yay\u0131lmas\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde azal\u0131r.<\/p>

Bilmekte fayda var: Omikron varyant\u0131 taraf\u0131ndan tetiklenen hastal\u0131\u011f\u0131n seyri, ortalama olarak delta varyant\u0131na g\u00f6re daha hafif seyretse de, iyi bir a\u015f\u0131 korumas\u0131 \u00f6nemini koruyor. \u00c7\u00fcnk\u00fc SARS-CoV-2 enfeksiyonu zarars\u0131z bir so\u011fuk alg\u0131nl\u0131\u011f\u0131 de\u011fildir, ancak bir\u00e7ok komplikasyonla (kan p\u0131ht\u0131la\u015fmas\u0131 veya inme gibi) ve uzun vadeli sonu\u00e7larla (COVID sonras\u0131 ve uzun s\u00fcreli) ili\u015fkilendirilebilir. \u0130yi bir a\u015f\u0131 korumas\u0131, ciddi hastal\u0131k ilerlemesine kar\u015f\u0131 korur ve bir enfeksiyon durumunda v\u00fccudun kontroll\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi sa\u011flar. Bunun nedeni, di\u011fer \u015feylerin yan\u0131 s\u0131ra, v\u00fccudun a\u015f\u0131lama sonucunda olu\u015fturdu\u011fu ve vir\u00fcsle erken ve hedefli bir \u015fekilde sava\u015fabilen baz\u0131 haf\u0131za h\u00fccreleridir (B ve T h\u00fccreleri olarak adland\u0131r\u0131l\u0131r). Bu ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri, ciddi hastal\u0131klara kar\u015f\u0131 korunmada kilit bir rol oynar ve tazeleme a\u015f\u0131s\u0131, bu korumay\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131r\u0131r.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131y\u0131 kimler olmal\u0131?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

STIKO, 12 ya\u015f ve \u00fcst\u00fc t\u00fcm vatanda\u015flara COVID-19 g\u00fc\u00e7lendirici a\u015f\u0131 \u00f6nermektedir.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Daimi A\u015f\u0131 Komisyonu (STIKO), a\u015f\u0131lama aral\u0131\u011f\u0131na ili\u015fkin tavsiyelerini de\u011fi\u015ftirmi\u015ftir ve gelecekte, sa\u011fl\u0131kl\u0131 bir ba\u011f\u0131\u015f\u0131kl\u0131k sistemine sahip 12 ya\u015f ve \u00fcst\u00fc ki\u015filer i\u00e7in temel a\u015f\u0131lama ile ilk tazeleme a\u015f\u0131s\u0131 aras\u0131nda en az 6 ayl\u0131k bir aral\u0131k \u00f6nermektedir. Tavsiye, hamileli\u011fin ikinci \u00fc\u00e7 ayl\u0131k d\u00f6neminden itibaren hamile kad\u0131nlar i\u00e7in de ge\u00e7erlidir. STIKO’ya g\u00f6re, \u00f6n hastal\u0131klar\u0131 olan 5 ila 11 ya\u015f aras\u0131ndaki \u00e7ocuklar\u0131n da temel a\u015f\u0131lardan 6 ay sonra tekrar a\u015f\u0131 olmalar\u0131 gerekir.<\/p>

\u0130yile\u015fenler veya bir a\u015f\u0131lama serisinden \u00f6nce, s\u0131ras\u0131nda veya sonras\u0131nda koronavir\u00fcs ile enfekte olan ki\u015filer i\u00e7in a\u015fa\u011f\u0131daki kurallar ge\u00e7erlidir:<\/p><\/div>

  • 2 dozluk serideki ilk a\u015f\u0131lamadan sonra enfekte olan ki\u015filer, enfeksiyondan 6 ay sonra ikinci a\u015f\u0131 dozunu almal\u0131d\u0131r.<\/p><\/li>

  • 2 dozluk serinin ikinci dozundan 3 ay sonra enfekte olan ki\u015filer, yaln\u0131zca 2. tazeleme a\u015f\u0131s\u0131 endikasyonu varsa tazeleme a\u015f\u0131s\u0131 yap\u0131lmal\u0131d\u0131r.<\/p><\/li>

  • \u0130lk a\u015f\u0131lamadan \u00f6nce enfekte olan ve daha sonra en az 4 hafta arayla bir a\u015f\u0131 dozu alan herkes, bir \u00f6nceki a\u015f\u0131lamadan 6 ay sonra tazeleme a\u015f\u0131s\u0131 yapt\u0131rabilir.<\/p><\/li>

  • En az 3 ayl\u0131k bir s\u00fcre i\u00e7inde iki kez enfekte olan a\u015f\u0131lanmam\u0131\u015f ki\u015filer, temel a\u015f\u0131lanm\u0131\u015f kabul edilir. Tazeleme a\u015f\u0131lamas\u0131 mevcut \u00f6nerilere g\u00f6re (genellikle 2. enfeksiyondan 3 ay sonra) yap\u0131lmal\u0131d\u0131r.<\/p><\/li>

  • 3 aydan k\u0131sa bir s\u00fcre sonra ikinci kez enfekte olan a\u015f\u0131lanmam\u0131\u015f ki\u015filer, temel ba\u011f\u0131\u015f\u0131klama i\u00e7in genellikle 2. enfeksiyondan 3 ay sonra bir a\u015f\u0131 dozuna ihtiya\u00e7 duyar. Tazeleme a\u015f\u0131lamas\u0131, mevcut \u00f6nerilere g\u00f6re (genellikle birincil ba\u011f\u0131\u015f\u0131klaman\u0131n son a\u015f\u0131 dozundan 3 ay sonra) yap\u0131lmal\u0131d\u0131r.<\/p><\/li>

  • M\u00fcmk\u00fcn olan en iyi ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 elde etmek i\u00e7in, 3 veya daha fazla koronavir\u00fcs enfeksiyonu ge\u00e7irmi\u015f a\u015f\u0131lanmam\u0131\u015f ki\u015filere de bir tazeleme a\u015f\u0131s\u0131 \u00f6nerilir. Son enfeksiyondan itibaren en az 3 ayl\u0131k bir ara g\u00f6zlemlenmelidir.<\/p><\/li><\/ul><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    D\u00f6rd\u00fcnc\u00fc korona a\u015f\u0131s\u0131:<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    STIKO, ikinci g\u00fc\u00e7lendirici a\u015f\u0131 tavsiyesini geni\u015fletiyor<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Belirli insan gruplar\u0131 i\u00e7in a\u015f\u0131 korumalar\u0131n\u0131 yenilemek – \u00fc\u00e7\u00fcnc\u00fc bir korona a\u015f\u0131s\u0131 yetmiyorsa, ek bir d\u00f6rd\u00fcnc\u00fc ( 2. G\u00fc\u00e7lendirme) korona a\u015f\u0131s\u0131 \u00f6zellikle yapmak – \u00f6nemlidir. STIKO, g\u00fcncel tavsiyesinde altta yatan bir hastal\u0131\u011f\u0131n sonucu olarak ciddi COVID-19 vakalar\u0131 riski y\u00fcksek olan 60 ya\u015f\u0131ndan b\u00fcy\u00fck ya\u015fl\u0131lar, 5 ya\u015f\u0131ndan b\u00fcy\u00fck ki\u015filer i\u00e7in 2. bir tazeleme a\u015f\u0131s\u0131 \u00f6nermektedir.<\/p>

    Bu insan gruplar\u0131, son olaydan (\u00f6nceki enfeksiyon veya COVID-19 a\u015f\u0131s\u0131) en ge\u00e7 alt\u0131 ay sonra bir mRNA a\u015f\u0131s\u0131 ile d\u00f6rd\u00fcnc\u00fc korona a\u015f\u0131s\u0131n\u0131 yapt\u0131rmal\u0131d\u0131r. Gerek\u00e7eli m\u00fcnferit durumlarda bu s\u00fcre 4 aya kadar k\u0131salt\u0131labilir. Bununla birlikte, imm\u00fcnolojik olarak sa\u011fl\u0131kl\u0131 ki\u015filerde, uzun s\u00fcreli koruma i\u00e7in daha uzun bir a\u015f\u0131lama aral\u0131\u011f\u0131 imm\u00fcnolojik olarak daha uygundur.<\/p>

    Gelecekte t\u00fcm vatanda\u015flar i\u00e7in ek tazelememe a\u015f\u0131lar\u0131n\u0131n gerekli olup olmayaca\u011f\u0131 ve gerekli olacaksa ne zaman gerekli olaca\u011f\u0131 hen\u00fcz \u00f6ng\u00f6r\u00fclememektedir. STIKO, \u015fu an i\u00e7in sa\u011fl\u0131kl\u0131 bir ba\u011f\u0131\u015f\u0131kl\u0131k sistemi olan 60 ya\u015f\u0131n alt\u0131ndaki ki\u015filer i\u00e7in ikinci bir tazelememe a\u015f\u0131s\u0131 \u00f6nermemektedir, \u00e7\u00fcnk\u00fc mevcut bilgilere g\u00f6re bu grup d\u00f6rd\u00fcnc\u00fc bir a\u015f\u0131dan \u00f6nemli \u00f6l\u00e7\u00fcde fayda g\u00f6rmemektedir.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Bu a\u015f\u0131lar aras\u0131ndaki fark nedir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Temel a\u015f\u0131laman\u0131n optimizasyonu, \u00fc\u00e7\u00fcnc\u00fc a\u015f\u0131lama, tazeleme a\u015f\u0131s\u0131 ve g\u00fc\u00e7lendirici a\u015f\u0131lama<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    Temel ba\u011f\u0131\u015f\u0131klama genellikle COVID-19’a kar\u015f\u0131 ba\u011f\u0131\u015f\u0131klama anlam\u0131na gelir; \u00f6rne\u011fin, onaylar\u0131na g\u00f6re bir (Johnson & Johnson’dan Janssen\u00ae) veya iki a\u015f\u0131 (BioNTech \/ Pfizer’den Comirnaty\u00ae veya Moderna’dan Spikevax\u00ae (Vaccine Moderna) veya AstraZeneca’dan Vaxzevria\u00ae).<\/p>

    E\u011fer temel a\u015f\u0131lama yeterli de\u011filse, temel a\u015f\u0131lamay\u0131 optimize etmek i\u00e7in \u00fc\u00e7\u00fcnc\u00fc bir a\u015f\u0131 veya ba\u015fka bir a\u015f\u0131 kullan\u0131l\u0131r. Bu, \u00f6rne\u011fin organ nakli gibi ciddi ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filer veya temel a\u015f\u0131 i\u00e7in Johnson & Johnson’dan tek doz Janssen\u00ae alm\u0131\u015f ki\u015filer i\u00e7in ge\u00e7erlidir. Bu durumda, \u00fc\u00e7\u00fcnc\u00fc a\u015f\u0131lama, ilk a\u015f\u0131lamadan d\u00f6rt hafta sonra m\u00fcmk\u00fcnd\u00fcr.<\/span><\/div>
    \u00a0<\/div>

    Hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131, azalan bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisini tekrar art\u0131rmak i\u00e7in yap\u0131lan yeni bir a\u015f\u0131d\u0131r. Bu, \u00f6rne\u011fin tetanoz veya \u00e7ocuk felci gibi \u00e7e\u015fitli bakteriyel veya viral patojenler i\u00e7in sabit zaman aral\u0131klar\u0131nda zaten bilinmektedir, b\u00f6ylece a\u015f\u0131 korumas\u0131 korunur. Korona a\u015f\u0131s\u0131 durumunda, hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131, tam bir temel a\u015f\u0131lama seriden sonra bir mRNA a\u015f\u0131s\u0131n\u0131n bir dozunun yeniden uygulanmas\u0131 anlam\u0131na gelir. Uzun vadede a\u015f\u0131 korumas\u0131n\u0131 s\u00fcrd\u00fcrmeye hizmet eder. Bu COVID-19 a\u015f\u0131s\u0131, genellikle temel a\u015f\u0131lamadan alt\u0131 ay sonra yenilenmelidir.<\/p>

    G\u00fc\u00e7lendirici (Booster) a\u015f\u0131, hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131n\u0131n e\u015f anlam\u0131d\u0131r. “Booster” terimi \u0130ngilizce’den gelir ve anlam\u0131 “g\u00fc\u00e7lendirici” dir.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    <\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t

    G\u00fcncellik: 09.2022,<\/em> Kaynak: Bundesministerium f\u00fcr Gesundheit<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    COVID-19’a Kar\u015f\u0131 Tazeleme A\u015f\u0131lar\u0131 G\u00fc\u00e7lendirici A\u015f\u0131lar Mevcut Omikron dalgas\u0131nda, tazeleme a\u015f\u0131lar\u0131 olarak da bilinen g\u00fc\u00e7lendirici a\u015f\u0131lar \u00f6zellikle \u00f6nemlidir. Daim\u00ee A\u015f\u0131 Komisyonu (STIKO), risk gruplar\u0131 i\u00e7in ikinci bir tazeleme a\u015f\u0131s\u0131 \u00f6nermektedir. Kimlere tazeleme a\u015f\u0131n\u0131n gerekti\u011fini ve kapsaml\u0131 koruma i\u00e7in g\u00fc\u00e7lendirici a\u015f\u0131n\u0131n neden \u00e7ok \u00f6nemli oldu\u011funu ve g\u00fc\u00e7lendirici a\u015f\u0131 ile ilgili t\u00fcm bilgileri burada bulabilirsiniz. G\u00fc\u00e7lendirici a\u015f\u0131 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/3568"}],"collection":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/comments?post=3568"}],"version-history":[{"count":102,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/3568\/revisions"}],"predecessor-version":[{"id":8551,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/3568\/revisions\/8551"}],"wp:attachment":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/media?parent=3568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}